Sarcopenia , as defined by reduced muscle mass alone , was found to be very prevalent in patients with lung cancer , regardless of body mass index , and where present was associated with poorer functional status and overall survival .
The effect of nutritional supplements and ATP infusions on muscle mass showed conflicting results .
There are very limited data on the correlation between degree of sarcopenia and muscle function , which has a non-linear relationship in older non-cancer population s. CONCLUSIONS Loss of muscle mass is a significant contributor to morbidity in patients with lung cancer .
OBJECTIVES There is growing awareness of the relationship between sarcopenia ( loss of muscle mass and function ) , and outcomes in cancer , making it a potential target for future therapies .
In order to inform future research and practice , we undertook a systematic review of factors associated with loss of muscle mass , and the relationship between muscle function and muscle mass in lung cancer , a common condition associated with poor outcomes .
Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study
Background A frequent manifestation of advanced NSCLC is malnutrition , even though there are many studies which relate it with a poor survival , its relation with toxicity has not yet been consistently reported . The aim of this study was to associate malnutrition and albumin serum levels with the occurrence of chemotherapy-induced toxicity in cisplatin plus paclitaxel chemotherapy-treated NSCLC . Methods We prospect ively evaluated 100 stage IV NSCLC patients treated with paclitaxel ( 175 mg/m2 ) and cisplatin ( 80 mg/m2 ) . Malnutrition was assessed using SGA prior treatment . Neutrophil Lymphocyte Ratio ( NLR ) and the Platelet Lymphocyte Ratio ( PLR ) were used to determine the presence of systemic inflammatory response ( SIR ) and were related to the development of toxicity . Toxicity was grade d according to NCI CTCAE version 3.0 after two chemotherapy cycles . Results Median age was 58 ± 10 years , 51 % of patients were malnourished , 50 % had albumin ≤3.0 mg/mL. NLR ≥ 5 was associated with basal hypoalbuminemia ( mean ranks , 55.7 vs. 39 p = 0.006 ) , ECOG = 2 ( 47.2 vs. 55.4 p = 0.026 ) and PLR ≥ 150 were significantly related with a basal body mass index ≤20 ( 56.6 vs. 43.5 ; p = 0.02 ) and hypoalbuminemia ( 58.9 vs. 41.3 ; p = 0.02 ) . Main toxicities observed after 2 cycles of chemotherapy were alopecia ( 84 % ) , nausea ( 49 % ) , neuropathy ( 46 % ) , anemia ( 33 % ) , lymphopenia ( 31 % ) , and leukopenia ( 30 % ) . Patients malnourished and with hypoalbuminemia developed more chemotherapy-induced toxicity overall when compared with those without malnutrition ( 31 vs 22 ; p = 0.02 ) and normal albumin ( mean ranks , 62 vs 43 ; p = 0.002 ) , respectively . Hypoalbuminemia was associated with anemia ( 56 vs 47 ; p = 0.05 ) , fatigue ( 58 vs 46 ; p = 0.01 ) , and appetite loss ( 57.1 vs 46.7 ; p = 0.004 ) compared with normal albumin . PLR ≥ 150 was related with the development of toxicity grade III/IV ( 59.27 vs. 47.03 p = 0.008 ) and anemia ( 37.9 vs 53.8 p = 0.004 ) . ConclusionS IR parameters were associated with malnutrition , weight loss and hypoalbuminemia . Chemotherapy-induced toxicity in NSCLC patients treated with  paclitaxel and cisplatin  was associated with malnutrition and hypoalbuminemia . Early nutritional assessment and support might confer beneficial effects
Sarcopenia , as defined by reduced muscle mass alone , was found to be very prevalent in patients with lung cancer , regardless of body mass index , and where present was associated with poorer functional status and overall survival .
The effect of nutritional supplements and ATP infusions on muscle mass showed conflicting results .
There are very limited data on the correlation between degree of sarcopenia and muscle function , which has a non-linear relationship in older non-cancer population s. CONCLUSIONS Loss of muscle mass is a significant contributor to morbidity in patients with lung cancer .
OBJECTIVES There is growing awareness of the relationship between sarcopenia ( loss of muscle mass and function ) , and outcomes in cancer , making it a potential target for future therapies .
In order to inform future research and practice , we undertook a systematic review of factors associated with loss of muscle mass , and the relationship between muscle function and muscle mass in lung cancer , a common condition associated with poor outcomes .